Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

$Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma$

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

by Vij, Ravi , Wu, Fan , Solomon, Scott R. , Patel, Krina , Cavo, Michele , Moreau, Philippe , Nooka, Ajay K. , Delforge, Michel , Manier, Salomon , Ailawadhi, Sikander , Piasecki, Julia , Cook, Mark , Berdeja, Jesus , Favre-Kontula, Linda , Giralt, Sergio , Rodriguez-Otero, Paula , Callander, Natalie , Truppel-Hartmann, Anna , Arnulf, Bertrand , Yang, Zhihong , Costa, Luciano J. , Bahlis, Nizar J.

in Adult / Antigens / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Cell therapy / Chimeric antigen receptors / Cytokines / Hematology / Hispanic Americans / Humans / Immunomodulation / Immunotherapy / Immunotherapy, Adoptive - adverse effects / Immunotherapy, Adoptive - methods / Leukemia / Lymphocytes B / Lymphocytes T / Lymphoma / Monoclonal antibodies / Multiple myeloma / Multiple Myeloma - drug therapy / Multiple Myeloma - therapy / Neurotoxicity / Oncology / Patients / Progression-Free Survival / Proteasome inhibitors / Proteasomes / Receptors, Chimeric Antigen - therapeutic use / Recurrence / Statistical analysis / Targeted cancer therapy / Treatments in Oncology

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

2023

Confirm

Do you wish to request the book?

$Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma$

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

$Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma$

Journal Article

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Vij, Ravi,

Wu, Fan,

Solomon, Scott R.,

Patel, Krina,

Cavo, Michele,

Moreau, Philippe,

Nooka, Ajay K.,

Delforge, Michel,

Manier, Salomon,

Ailawadhi, Sikander,

Piasecki, Julia,

Cook, Mark,

Berdeja, Jesus,

Favre-Kontula, Linda,

Giralt, Sergio,

Rodriguez-Otero, Paula,

Callander, Natalie,

Truppel-Hartmann, Anna,

Arnulf, Bertrand,

Yang, Zhihong,

Costa, Luciano J.,

Bahlis, Nizar J.

2023

Overview

A phase 3 trial of BCMA-specific CAR T cells in relapsed and refractory myeloma showed an advantage over standard therapy (progression-free survival, 13.3 vs. 4.4 months); 39% of patients in the ide-cel group had a complete response.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Antigens

/ Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Agents, Immunological - therapeutic use

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Cell therapy